Peer-reviewed veterinary case report
Chemotherapy with doxorubicin and cyclophosphamide for cats
By Barber, L G et al.·Published in Journal of the American Animal Hospital Association·2000·Department of Clinical Studies, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Combined doxorubicin and cyclophosphamide chemotherapy for nonresectable feline fibrosarcoma.
- Species:
- cat
Plain-English summary
A group of 12 cats with nonremovable fibrosarcoma tumors, which can occur at vaccination sites, were treated with a combination of two chemotherapy drugs, doxorubicin and cyclophosphamide. About half of the cats showed a significant reduction in tumor size, but the effects didn't last long, with an average response lasting just over four months. Unfortunately, all the cats eventually experienced disease progression. However, those that did respond to the chemotherapy lived longer compared to those that did not respond, with an average survival of about eight months for responders.
People also search for: cat fibrosarcoma treatment · chemotherapy for cats · vaccine-associated sarcoma in cats · doxorubicin side effects in cats
Abstract
A retrospective evaluation was performed on 12 cats with nonresectable, histopathologically confirmed fibrosarcomas that were treated with doxorubicin and cyclophosphamide chemotherapy. All of the tumors were located in sites potentially used for vaccination. Six cats had a greater than 50% decrease in gross tumor burden. However, the responses were not durable, with a median response duration of 125 days. All cats developed progressive disease. When animals that received other treatments after doxorubicin-based chemotherapy were eliminated from the analysis, median survival time was significantly longer for cats that responded to chemotherapy compared with the median survival time for nonresponders (242 and 83 days, respectively). These findings may serve as a basis for further evaluating the role of chemotherapy in the treatment of vaccine-associated sarcomas.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/10997517/